Literature DB >> 17699224

Urinary tract infections in patients with chronic renal insufficiency.

David N Gilbert1.   

Abstract

Despite an increasing population of patients with chronic renal insufficiency, the literature on the management of urinary tract infections (UTI) in these patients is sparse. Patients with underlying diabetes are a specific population at risk. Antimicrobial treatment of UTI requires adequate serum, renal, parenchymal, and urine concentrations of drugs with antibacterial activity versus the etiologic organism. Sulfamethoxazole and nitrofurantoin are examples of drugs with low and likely inadequate urine concentrations in patients with creatinine clearances of <50 ml/min. Urine concentrations of ciprofloxacin and levofloxacin remain sufficient as renal function fails, whereas the concentrations of gemifloxacin and moxifloxacin are too low to predict efficacy. More investigative work is needed in the management of UTI in patients with poor renal function.

Entities:  

Mesh:

Year:  2006        PMID: 17699224     DOI: 10.2215/CJN.01931105

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  16 in total

1.  Influence of type and neutralisation capacity of antacids on dissolution rate of ciprofloxacin and moxifloxacin from tablets.

Authors:  Alija Uzunović; Edina Vranić
Journal:  Bosn J Basic Med Sci       Date:  2009-02       Impact factor: 3.363

2.  A screen for and validation of prodrug antimicrobials.

Authors:  Laura E Fleck; E Jeffrey North; Richard E Lee; Lawrence R Mulcahy; Gabriele Casadei; Kim Lewis
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

3.  Nitrofurantoin safety and effectiveness in treating acute uncomplicated cystitis (AUC) in hospitalized adults with renal insufficiency: antibiotic stewardship implications.

Authors:  B A Cunha; C B Cunha; B Lam; J Giuga; J Chin; V F Zafonte; S Gerson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-02       Impact factor: 3.267

4.  The urinary antibiotic 5-nitro-8-hydroxyquinoline (Nitroxoline) reduces the formation and induces the dispersal of Pseudomonas aeruginosa biofilms by chelation of iron and zinc.

Authors:  A Sobke; M Klinger; B Hermann; S Sachse; S Nietzsche; O Makarewicz; P M Keller; W Pfister; E Straube
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

5.  Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care.

Authors:  Arjen F J Geerts; Willemijn L Eppenga; Rob Heerdink; Hieronymus J Derijks; Michel J P Wensing; Toine C G Egberts; Peter A G M De Smet
Journal:  Eur J Clin Pharmacol       Date:  2013-05-10       Impact factor: 2.953

6.  Effect of pravastatin and fosinopril on recurrent urinary tract infections.

Authors:  Koen B Pouwels; Sipke T Visser; Eelko Hak
Journal:  J Antimicrob Chemother       Date:  2012-10-30       Impact factor: 5.790

7.  Isolation Rate and Clinical Significance of Uropathogens in Positive Urine Cultures of Hemodialysis Patients.

Authors:  Katerina G Oikonomou; Adib Alhaddad
Journal:  J Glob Infect Dis       Date:  2017 Apr-Jun

8.  Risk Factors for Development of Acute Kidney Injury in Patients with Urinary Tract Infection.

Authors:  Chih-Yen Hsiao; Huang-Yu Yang; Meng-Chang Hsiao; Peir-Haur Hung; Ming-Cheng Wang
Journal:  PLoS One       Date:  2015-07-27       Impact factor: 3.240

9.  Antibiotic Susceptibility Patterns and Prevalence of Some Extended Spectrum Beta-Lactamases Genes in Gram-Negative Bacteria Isolated from Patients Infected with Urinary Tract Infections in Al-Najaf City, Iraq.

Authors:  Heba Takleef Majeed; Ahmed Abduljabbar Jaloob Aljanaby
Journal:  Avicenna J Med Biotechnol       Date:  2019 Apr-Jun

10.  Plasma and Renal Cortex Meropenem Concentrations in Patients Undergoing Percutaneous Renal Biopsy.

Authors:  Rodrigo A Sepúlveda; Patricio Downey; Dagoberto Soto; Kwok-Yin Wong; Yun-Chung Leung; Lok-Yan So; Max Andresen
Journal:  Biomed Res Int       Date:  2019-11-19       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.